Ex Parte Abo et al - Page 2

                Appeal 2007-4214                                                                             
                Application 10/330,372                                                                       
                      Claims 6, 45, 49, and 511 stand rejected under 35 U.S.C. § 112,                        
                second paragraph, as being indefinite for failing to particularly point out and              
                distinctly claim the subject matter that applicant regards as the invention.                 
                      Claim 6 is representative of the claims on appeal, and is dependent on                 
                claim 1.  Claims 1 and 6 are reproduced below:                                               
                1. An isolated full-length Chp polypeptide, or a polypeptide fragment                        
                thereof, wherein (i) said Chp polypeptide or polypeptide fragment thereof                    
                has about 95% or greater identity to the amino acid sequence presented as                    
                SEQ ID NO: 2, and (ii) said Chp polypeptide or polypeptide fragment                          
                thereof has at least one biological activity selected from the group consisting              
                of a PAK regulatory domain binding activity, a PAK kinase stimulatory                        
                activity, a JNK kinase stimulatory activity, a cytoskeletal-reorganizing                     
                activity, a Chp-specific immunogenic activity directed to SEQ ID NO:2 and                    
                combinations thereof.                                                                        
                6. The isolated Chp polypeptide or polypeptide fragment of claim 1,                          
                wherein said fragment consists essentially of a polypeptide having a                         
                sequence selected from the group consisting of SEQ ID NO:6, SEQ ID                           
                NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:12, and SEQ ID NO:13.                              

                      The Examiner objects to the use of the transition phrase “consisting                   
                essentially of.”  According to the Examiner,                                                 
                            As the dependent claims, claims 6 and 49 must be limited                         
                      to Chp polypeptide or Chp polypeptide fragment thereof that                            
                      has about 95% or greater identity to the amino acid sequence                           
                      presented as SEQ ID NO:2 (236 amino acids).  The sequences                             
                      of SEQ ID NO:6 (32 amino acids), SEQ ID NO:7 (180 amino                                
                      acids), SEQ ID NO:8 (26 amino acids), SEQ ID NO:9 (17                                  
                      amino acids), SEQ ID NO:12 (28 amino acids), and SEQ ID                                
                      NO: 13 (17 amino acids) are fragments of SEQ ID NO:2.  Due                             

                                                                                                            
                1 Claims 1, 3-8, 45-49, 51, and 52 appear to be pending, with claims 2, 9-44,                
                and 50 being cancelled, and claims 1, 3-5, 7, 8, 46-48, and 52 being                         
                indicated as being allowable (Br. 5).                                                        
                                                     2                                                       

Page:  Previous  1  2  3  4  5  6  Next

Last modified: September 9, 2013